New drugs and dosage forms

Abstract

Adalimumab-adbm injection (Boehringer Ingelheim Pharmaceuticals): The biosimilar to adalimumab is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderately to severely active Crohn’s disease, moderately to severely active ulcerative colitis, or chronic moderate-to-severe plaque psoriasis. Adalimumab-adbm is also indicated for the treatment of patients 4 years of age or older with moderately to severely active polyarticular juvenile idiopathic arthritis. The tumor necrosis factor blocker is subject to FDA Medication Guide requirements. Amantadine extended-release capsules (Adamas Pharma): The drug is indicated for the treatment of dyskinesia in patients with Parkinson’s disease who are receiving levodopa-based therapy. Inotuzumab ozogamicin for injection (Besponsa, Pfizer): The antibody–drug conjugate directed against CD22 is indicated for the treatment of adults with B-cell precursor acute lymphoblastic leukemia that has relapsed or not responded to treatment. Kit for the preparation of technetium (Tc) 99m exametazime injection (Drax Exametazime, Jubilant DraxImage): Tc 99m exametazime is a radioactive diagnostic agent indicated for use during leukocyte-labeled scintigraphy imaging to localize intraabdominal infection and inflammatory bowel disease.